Sheue-Fen Tzeng

Title: Sheue-Fen Tzeng: Innovator in Prostate Cancer Biomarkers

Introduction

Sheue-Fen Tzeng is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of medical research, particularly in the area of prostate cancer. His work focuses on developing biomarkers that can predict the progression of this disease, which is crucial for improving patient outcomes.

Latest Patents

Tzeng holds a patent for "Biomarkers for predicting prostate cancer progression." This invention relates to biomarkers, methods, and assay kits designed to predict prognosis and monitor the progression of prostate cancer. The biomarkers include gene products such as core 1 beta-3-galactosyltransferase (C1GALT1) and ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3GAL1), along with their saccharide substrates/products and galectin-4 gene products. He has 1 patent to his name.

Career Highlights

Tzeng is affiliated with Academia Sinica, a prestigious research institution in Taiwan. His work has garnered attention for its potential impact on cancer diagnostics and treatment. He is dedicated to advancing the understanding of prostate cancer through innovative research.

Collaborations

Some of his notable coworkers include Pei-wen Hsiao and Chin-Hsien Tsai. Their collaborative efforts contribute to the ongoing research and development of effective cancer biomarkers.

Conclusion

Sheue-Fen Tzeng is a key figure in the field of prostate cancer research, with a focus on developing predictive biomarkers. His contributions are vital for enhancing the prognosis and monitoring of this disease.